By integrating structural, clinical, and computational perspectives, this review highlights current knowledge and emerging directions in CDK4/6 research that may advance the development of more personalized therapies for HR+/HER2- breast cancer, while accounting for both intrinsic and de novo resistance mechanisms. This evidence concerns the gene ERBB2 and breast cancer.